A Retrospective Study to Examine Healthcare Costs Related to Cardiovascular Events in Individuals with Hyperlipidemia by unknown
ORIGINAL RESEARCH
A Retrospective Study to Examine Healthcare Costs
Related to Cardiovascular Events in Individuals
with Hyperlipidemia
Henry J. Henk . Carly J. Paoli . Shravanthi R. Gandra
To view enhanced content go to www.advancesintherapy.com
Received: August 28, 2015 / Published online: November 19, 2015
 The Author(s) 2015. This article is published with open access at Springerlink.com
ABSTRACT
Introduction: Few studies have demonstrated
the cost burden of cardiovascular events (CVEs)
among patients with hyperlipidemia. The
primary objective of this study was to
determine the mean costs associated with
CVEs among patients with hyperlipidemia by
follow-up time period. Secondary objectives of
this study included characterizing costs by CVE
type and coronary heart disease (CHD) risk.
Methods: This retrospective cohort study used
longitudinal claims to calculate payer costs
according to CHD risk level and type of CVE,
during several follow-up periods (acute and
short-term, comprising year 1; plus years 2 and
3).
Results: There were 193,385 patients with
hyperlipidemia with a CVE. Costs in the
acute (30-day) period were highest ($22,404)
driven by inpatient care (77%). Costs
remained high ($15,133 in year 3) with
ambulatory care (from 14% in acute to 37%
in year 3) and pharmaceutical costs (from 2%
in acute to 24% in year 3) representing a
greater proportion. After second and third
CVEs, acute costs were lower than for the
first CVE. But in the post-acute periods, costs
were higher after second and third CVEs than
after first CVEs. Acute costs varied
considerably by type of CVE ($9149 for
transient ischemic attack to $54,251 for
coronary artery bypass graft; P\0.001), but
post-acute costs were more similar across
types. Costs differed by baseline CHD risk for
all follow-up periods (P\0.001), but less than
by CVE type. As expected, patients without
CVEs had significantly lower costs.
Conclusion: Among patients with
hyperlipidemia, the economic burden of CVEs
is substantial up to 3 years after a CVE. Costs
remain high after subsequent CVEs and actually
increase for non-inpatient utilization.
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The treatment and prevention of
hyperlipidemia (elevated low-density
lipoprotein-C [LDL-C] levels) have been a
significant public health focus for many years.
Elevated LDL-C is associated with increased risk
of developing coronary heart disease (CHD), the
most common cause of death in the United
States (US) [1, 2]. Meta-analysis of 26 clinical
trials demonstrated that risk of any
cardiovascular event (CVE) was reduced by
20% and mortality was reduced by 10%, for
every 38.7 mg/dL reduction of LDL-C [2].
Another more recent meta-analysis
demonstrated among 40 trials of
lipid-modifying drugs that LDL-C, but not
high-density lipoprotein, levels were predictive
of both primary and secondary CVEs [3]. The
newest American College of Cardiology/
American Heart Association Task Force on
Practice Guidelines defined the characteristics
of patients who would most benefit from statin
therapy to treat hyperlipidemia and prevent
CVEs, including atherosclerotic cardiovascular
disease (ASCVD), elevated LDL-C, diabetes, and
high estimated 10-year ASCVD risk [4]. Yet,
even though high LDL-C affects 71 million
(33.5%) US adults, \50% of affected
individuals receive treatment [1].
Cardiovascular disease (CVD) and stroke are
major contributors of disease burden in the US
[5], and globally [6]. In the US, the annual direct
cost of CVD and stroke was estimated at
$192.1 billion in 2009: Approximately
$86.1 billion for inpatient stays, $46.7 billion
for outpatient or office-based visits, and
$31.8 billion for prescription drugs [7]. Costs
related to CVEs include acute treatment,
secondary prevention measures, recurrent
CVEs, and rehabilitation [7–14]. Age,
hyperlipidemia, impaired renal function,
depression, and concurrent CVEs have been
shown to impact costs [8, 15–19].
Previous research has been valuable in
demonstrating the great cost burden of CVEs
[8, 16, 20–22], yet only one report specifically
assessed cohorts of patients with
hyperlipidemia. Given that adequate
hyperlipidemia treatment lowers the risks
associated with CVEs, it is important to obtain
current cost estimates associated with CVEs.
The primary objective of this study was to
determine the mean costs associated with
CVEs among patients with hyperlipidemia by
follow-up time period. Secondary objectives of
this study included characterizing costs by CVE
type and CHD risk; as a reference, we provide
cost estimates for a sample of non-CVE patients
from the same population.
METHODS
Study Design
This was a retrospective cohort study using
longitudinal administrative healthcare claims
data. Healthcare costs were calculated by
baseline level of CHD risk and type of CVE
during several follow-up periods: Acute (days
0–30), short-term (days 31–365), first year
(days 0–365), second year (days 366–730),
and third year (days 731–1095). Costs of first
and subsequent CVEs were also obtained.
Costs were compared to patients not
experiencing a CVE but with similar baseline
characteristics.
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Data Sources
Data were obtained from the Optum Research
Database (ORD), which contains de-identified
medical and pharmacy claims data annually for
approximately 14 million individuals who are
enrolled in a commercial (fully insured or
self-insured employer line of business) or
Medicare Advantage plan. This paper reports
results among commercial health plan enrollees
only. The population contained within ORD is
geographically diverse and fairly representative
across the US, with a concentration of patients
in the South. The ORD does not contain
protected health information and is fully
compliant with federal guidance on human
subjects research, thus IRB review and
approval was not required [23].
Study Sample
Subjects included members C18 years old with
hyperlipidemia identified by a claim for a
hyperlipidemia drug (see Table S1 in the
online supplementary material) or an
International Classification of Diseases Clinical
Modification 9 (ICD-9-CM) [24] code for
hyperlipidemia (272.0, 272.1, 272.2, 272.4,
and 272.9) between January 1, 2006 and July
31, 2012 (identification period). The earliest
date of a qualifying claim was the
hyperlipidemia date.
Multiple types of CVEs [myocardial
infarction (MI), ischemic stroke (IS), transient
ischemic attack (TIA), heart failure (HF),
unstable angina (UA), percutaneous coronary
intervention (PCI), and coronary artery bypass
graft (CABG)] were studied. The CVEs were
identified by the presence of ICD-9-CM or
healthcare common procedure coding system
(HCPCS) [25] codes: C1 ICD-9-CM facility
claims for hospitalizations for MI, IS, TIA, HF,
or UA, or C1 ICD-9-CM or HCPCS procedure
claims for PCI or CABG (see Table S2 in the
online supplementary material). For patients
experiencing a CVE, their index date was the
date of the first CVE following their
hyperlipidemia date. The baseline period
included the 12-month period prior to the
index date. Follow-up was a period of variable
length 30 days to 3 years, following (and
including) the index date until the earlier of
disenrollment, August 31, 2012, or 36 months
after the index date. Continuous enrollment
was required from 12 months prior to the index
date.
As a reference, individuals were identified
who did not have a CVE, but had similar
baseline characteristics, including age, gender,
health plan region, health plan type, history of
chronic comorbid conditions based on
ICD-9-CM diagnoses [hemorrhagic stroke,
carotid artery disease, chronic renal failure,
chronic obstructive pulmonary disease
(COPD), asthma, mental disorders, and
osteoarthritis]; number of inpatient
hospitalizations in baseline period; and time
between hyperlipidemia date and index date.
Due to the number of variables, propensity
scores (PS) were estimated for each patient using
a logistic regression model. Non-CVE patients
having similar PS as those experiencing a CVE
were then selected. For these non-CVE patients,
the index date was defined as their
hyperlipidemia date plus a randomly
generated number of days (to represent time
between hyperlipidemia diagnosis and event
‘index’ date), based upon a gamma distribution.
A gamma distribution was chosen because it
best represented the distribution of days
between hyperlipidemia date and first CVE
among patients who had a CVE.
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Study Measures
Demographic and Clinical Characteristics
Patient demographics examined at the index
date for all patients included age, gender, and
US Census geographic region (Northeast,
Midwest, South, West) [26]. Clinical
characteristics examined during the baseline
period included index CVE type and CHD risk
level, as defined by the Adult Treatment Panel
(ATP) III [27]; evidence of hemorrhagic stroke,
carotid artery disease, chronic renal failure,
COPD, asthma, mental disorders, or
osteoarthritis; and number of all-cause
inpatient hospitalizations, and emergency
room and ambulatory visits (see Table S3 in
the online supplementary material). The ATP III
risk levels are defined as follows: high risk—any
CHD or CHD risk equivalent; moderate risk—2
CHD risk factors; or low risk—0 to 1 CHD risk
factors.
For individuals with more than one CVE
type, the index date was assigned based on the
CVE coded in the principal or first-listed
position. Second and third CVEs within
30 days following a CVE of the same type did
not qualify as a new CVE. The second or third
CVE date was the earliest date of the second and
third qualifying CVE(s).
Healthcare Costs
Costs were reported for the follow-up periods
and represented the sum of all health plan- and
patient-paid amounts for all medical
(ambulatory [office and outpatient
hospitalization] visits, emergency room visits,
inpatient hospitalization, and other services)
and retail pharmacy services during the time of
enrollment in the health plan. Costs prior to
2012 were adjusted to 2012 costs using the
medical care component of the Consumer Price
Index [28]; those incurred by other payers or
managed through coordination of benefits (e.g.,
Medicare part A/B) were excluded.
Statistical Analysis
To estimate the health care cost and resource
utilization of patients, in the same insured
population, with hyperlipidemia but not
experiencing a CVE we used a sample with
similar baseline characteristics as patients who
did experience a CVE. Given the number of
baseline characteristics, we selected patients
with hyperlipidemia not experiencing a CVE
who had a similar propensity of having a CVE as
the CVE cohort. The propensity calculation
included hyperlipidemia date, index date, age,
gender, health plan region, health plan type,
chronic comorbid conditions (see Table S3 in
the online supplementary material), number of
inpatient hospitalizations in baseline period,
and time to CVE. Because patients experiencing
a CVE often have higher risk levels, costs within
the non-CV cohorts are presented by risk level
strata.
Analyses were conducted using SAS version
9.2 (SAS Institute, Inc., Cary, NC, USA) or Stata
SE version 11 (StataCorp LP, College Station,
TX, USA). The conventional significance level
a = 0.05 was used.
RESULTS
Sample Description
The sample included 193,385 commercial
enrollees with hyperlipidemia and a CVE who
met study criteria. Their average [± standard
deviation (SD)] age was 62.0 (±12.1) years, with
the majority of patients being male (62.5%), at
least 55 years of age, and having high baseline
CHD risk (Table 1). During the 12 months prior
to their CVE, nearly 34% had been hospitalized
Adv Ther (2015) 32:1104–1116 1107
and mean baseline total costs were $25,250
(±64,970). A relatively low proportion of
patients had evidence of stroke, carotid artery
disease, or COPD. However, mental disorders
and osteoarthritis were common. The average
length of follow-up after a CVE was 530 days
(median = 456) with 94% (n = 182,416) being
enrolled during the short-term period, 57%
(n = 109,950) during the second year, and 33%
(n = 63,869) during the third year.
Costs Following a CVE
The largest total cost occurred in the first year,
and most notably in the first 30 days following a
CVE (acute period), driven primarily by
inpatient costs at $22,404 (comprising 77% of
first year costs) while 68% of patients were
hospitalized in the first 30 days (average length
of stay 4.8 days). However, over time inpatient
rates decreased to approximately 19% (average
length of stay 2.4–3.3 days) in the second and
third years. Though costs remained high
($15,133 in year 3) over time, with inpatient
Table 1 Baseline characteristics
Characteristic Total
(N5 193,385)




















Hemorrhagic stroke 2505 (1.30)
Carotid artery disease 16,202 (8.38)
Chronic renal failure 21,141 (10.93)
Chronic obstructive pulmonary disease 14,212 (7.35)
Asthma 17,076 (8.83)
Mental disorders 62,524 (32.33)
Osteoarthritis 45,594 (23.58)
Baseline CHD risk
Low risk: 0–1 CHD risk factors 31,307 (16.19)




High risk: any CHD or CHD risk
equivalent
128,566 (66.48)
Hospitalized in baseline period
(any cause)
65,440 (33.84)
Emergency room visit in baseline
period (any cause)
96,448 (49.87)
Number of ambulatory visits in
baseline period (any cause), mean
(SD)
21.67 (20.69)
Values are presented as n (%) unless otherwise stated
CHD coronary heart disease, SD standard deviation
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costs accounted for a lower proportion of costs
and ambulatory care (from 14% in acute to
37% in year 3) and pharmaceutical costs rose
(from 2% in acute to 24% in year 3) (Table 2).
This pattern continued for those experiencing
a second (n = 84,386) and third CVE
(n = 52,977), but in contrast, costs were
greater in the short-term versus acute period
(Fig. 1). These patterns were similar across CVE
type.
Costs by CVE Risk Level
The costs for each of the follow-up periods, by
risk level, are shown in Table 3 and Fig. 2.
Interestingly, mean costs differed by baseline
CHD risk for all time periods (overall P\0.001),
but without a consistent pattern in the acute
period for the CVE cohort. However,
short-term, second-year, and third-year
patterns were more similar (Fig. 2) between
years and among risk levels, with third-year
costs lower than second-year costs.
Costs by Type of CVE
Table 3 and Fig. 2 also show costs for the
different event types studied. Acute costs
varied considerably by type of CVE, ranging
from $9149 for TIA to $54,251 for CABG
(overall P\0.001). Although remaining
significantly different (overall P\0.001) by
types, costs beyond the first 30 days
(short-term, second year, third year) varied less
by index CVE type. In the second and third
years, HF was the costliest type, while CABG was
the least costly.
Costs Among Patients with no CVE
A total of 154,354 patients with hyperlipidemia
but not experiencing a CVE were selected
among those with a similar PS to patients
experiencing a CVE. Characteristics used in
the PS model were similar except a few
distinctions (e.g., age and risk level) which can
be attributed to the fact that patients with CVEs
are typically older and at higher risk due to the
inherent nature of the disease. As expected,
patients without a CVE were found to have
much lower costs in each of the time periods
overall and within each CHD risk level (Fig. 2).
Acute period costs for those with no CVE were
very low compared to those with a CVE, but
costs over the follow-up time periods in both
groups were substantial and remained relatively
steady across risk level. However, follow-up
costs were double for those experiencing a
CVE than those not experiencing a CVE.
DISCUSSION
The importance of this study was the focus
upon the costs incurred by commercial payers
following a CVE within a population of patients
with hyperlipidemia, to further understand the
economic burden associated with CVD among
this high-risk population.
Prior claims-based studies have
demonstrated recurrent hospitalizations and
follow-up care are major contributors to
CVE-related costs, although direct comparison
between studies is hindered by differing costs
captured. Roberts et al. [30] reported acute
stroke-related hospitalization costs of $16,889,
plus $2203 for additional cardiovascular-related
medical services, similar to our all-cause costs
for patients having stroke events.
Engel-Nitz et al. [20] demonstrated patients
with recurrent IS had higher hospitalization
costs following subsequent stroke ($17,121)
compared to their first stroke ($15,634).
Among all CVE types combined in the current
study, first year inpatient costs were also higher
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for subsequent CVEs, but non-inpatient costs
accounted for greater proportions. Other studies
evaluated CVE costs with respect to
hypertension (Duh et al. [18]) and diabetes
(Straka et al. [16]) comparing costs between
patients with and without CVEs. Similar to the
current study, these authors found CVEs
imparted significantly greater inpatient,
outpatient, and prescription costs, and high
continuing costs during up to three follow-up
years [16]. Chapman et al. [8] conducted an
observational study on costs of CVEs using
dyslipidemia as one of the potential
confounders in a multivariable analysis. In
their study, mean total costs were at $33,563
for the first year, compared to $41,937 in the
current study [8]. Higher estimates in the
current study may be attributed to Chapman
et al.’s inclusion of non-commercial insurance
plans (Medicaid, Medicare, etc.), or attributing
$0 costs to disenrolling patients, as well as
different patient populations/sample selection,
and inflation.
A recent study by Punekar et al. [22]
investigated healthcare resource utilization
and costs. Some similarities exist between
studies: Those with CVEs had higher
healthcare costs than matched controls, and
CABG and TIA events were associated with
highest and lowest costs, respectively [22].
Punekar et al. [22] found total 2-year costs for
their secondary prevention, high risk, and
primary prevention cohorts of $46,555,
$46,739, and $39,673, respectively. The costs
in the current study for high, moderate, and low
risk categories were $42,903, $38,194, and
$41,978, respectively, for the first year
post-CVE, and $18,186, $14,331, $13,645,
Fig. 1 Total costs (in $USD) following ﬁrst, second, and third CVE. CVE cardiovascular event, IP inpatient
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Table 3 Average costs ($USD) for CVE group by risk level and type of CVE following the index CVE
First year Second year Third year
Total Acute Short Total Total
Risk level
Low risk: 0–1 CHD risk factors
N 31,307 31,307 29,909 18,038 10,396
Mean 41,978 24,509 18,264 13,645 11,738
SD 73,773 44,594 52,401 42,773 35,603
Moderate risk: 2 CHD risk factors
N 33,512 33,512 31,504 18,666 10,677
Mean 38,194 21,122 18,072 14,331 13,043
SD 66,452 39,406 48,145 46,880 37,190
High risk: any CHD or CHD risk equivalent
N 128,566 128,566 121,003 73,246 42,796
Mean 42,903 22,226 21,867 18,186 16,480
SD 73,676 41,416 55,992 49,610 43,728
Type of CVE
Myocardial infarction
N 38,851 38,851 36,285 21,682 12,558
Mean 48,131 30,258 19,083 14,536 12,745
SD 73,948 48,922 48,000 39,139 33,825
Ischemic stroke
N 24,757 24,757 22,920 12,661 6944
Mean 39,608 20,086 20,996 15,072 13,528
SD 80,497 45,600 59,176 43,219 39,748
Percutaneous coronary intervention
N 31,455 31,455 30,589 20,203 12,327
Mean 39,720 23,539 16,593 15,228 14,215
SD 46,733 22,335 37,426 34,154 30,601
Coronary artery bypass graft
N 10,998 10,998 10,664 6962 4213
Mean 69,598 54,251 15,804 11,671 11,003
SD 71,263 55,042 37,180 28,822 34,267
Angina
N 18,970 18,970 18,349 11,763 7226
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respectively, for the second year post-CVE.
Differences in costs between studies are likely
due to differing risk definitions, health plan
inclusion, and propensity scoring strategies.
In summary, previous claims studies have
shown that patients having CVEs incur
substantially greater costs than those with no
CVE, even among varying datasets with
differing inclusion criteria. These costs were
largely driven by inpatient utilization. This
study demonstrating continuing economic
burden of CVEs over time in patients with
hyperlipidemia is supported by previous
findings. Furthermore, this research provides a
valuable base to support future studies on the
impact of lipid-lowering medications and
predicting costs projected over longer time
periods.
LIMITATIONS
Certain limitations of administrative claims
studies should be considered. Misclassification
and miscoding are possible and diagnostic
codes are not definitive proof of disease. The
analytic dataset may be affected by the lack of
data not available from claims databases, such
as certain lab values, family history and
smoking status. Also, retrospective studies are
prone to spurious associations attributed to bias
by way of confounding variables [29, 31, 32],
some of which represent unknown risk factors.
However, the propensity scores allowed
identification of a sample of patients that was
balanced across several demographic and
known relevant clinical characteristics. The
severity of disease represented by the
matching factors may differ for those having
and not having a CVE. Finally, the findings in
this study are not generalizable to a
non-commercially insured population.
CONCLUSIONS
The costs associated with CVEs among patients
with hyperlipidemia are high and remain
elevated. The CVE costs are largely driven by
inpatient hospitalization in the first 30 days,
Table 3 continued
First year Second year Third year
Total Acute Short Total Total
Mean 29,069 14,077 15,465 14,131 13,971
SD 47,035 26,364 35,364 32,062 32,596
Transient ischemic attack
N 17,694 17,694 16,998 10,429 6038
Mean 23,089 9149 14,416 12,653 11,873
SD 45,322 21,863 36,596 32,618 35,226
Heart failure
N 50,660 50,660 46,611 26,250 14,563
Mean 45,098 17,644 29,672 24,860 21,859
SD 91,161 44,566 74,990 73,803 59,825
CHD coronary heart disease, CVE cardiovascular event, SD standard deviation
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but significant costs persist for several years.
After the acute period, outpatient and
ambulatory costs represent a larger proportion
of costs. The main driver of CVE costs in this
study is CHD risk level, with costs varying by
index CVE type. To assess the impact of
lipid-lowering medications, a similar study
including variables on medication use is
necessary. Future clinical decision-making and
cost-effectiveness studies will benefit from these
findings.
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